

## BIM-23190

<b>Cat. No.:</b>	HY-P3124
<b>CAS No.:</b>	182153-96-4
<b>Molecular Formula:</b>	C <sub>57</sub> H <sub>79</sub> N <sub>13</sub> O <sub>12</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	1202.45
<b>Sequence:</b>	{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-Cys-Tyr-{D-Trp}-Lys-{Abu}-Cys-Thr-NH <sub>2</sub> (Disulfide bridge: Cys2-Cys7)
<b>Sequence Shortening:</b>	{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-CY-{D-Trp}-K-{Abu}-CT-NH <sub>2</sub> (Disulfide bridge: Cys2-Cys7)
<b>Target:</b>	Somatostatin Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits K <sub>i</sub> values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly <sup>[1][3]</sup> .	
<b>In Vitro</b>	BIM-23190 tends to mildly stimulate PRL secretion <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	BIM-23190 (50 µg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma) <sup>[2]</sup> .
	<b>Dosage:</b>	50 µg/mouse
	<b>Administration:</b>	Injected twice a day for 19 days.
	<b>Result:</b>	Significantly reduced the tumor growth rate.

### REFERENCES

- [1]. I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. *J Clin Invest.* 1997 Nov 1;100(9):2386-92.
- [2]. Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. *Am J Physiol Endocrinol Metab.* 2009 Nov;297(5):E1078-88.
- [3]. T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. *J Pharmacol Exp Ther.* 1998 Apr;285(1):95-104.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA